Cargando…
Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801456/ https://www.ncbi.nlm.nih.gov/pubmed/20066161 http://dx.doi.org/10.1155/2009/348910 |
_version_ | 1782175923030720512 |
---|---|
author | Oosten, A. W. Seynaeve, C. Schmitz, P. I. M. den Bakker, M. A. Verweij, J. Sleijfer, S. |
author_facet | Oosten, A. W. Seynaeve, C. Schmitz, P. I. M. den Bakker, M. A. Verweij, J. Sleijfer, S. |
author_sort | Oosten, A. W. |
collection | PubMed |
description | Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS. The overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months respectively. No statistically significant differences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group. If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender. |
format | Text |
id | pubmed-2801456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28014562010-01-11 Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin Oosten, A. W. Seynaeve, C. Schmitz, P. I. M. den Bakker, M. A. Verweij, J. Sleijfer, S. Sarcoma Research Article Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS. The overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months respectively. No statistically significant differences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group. If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender. Hindawi Publishing Corporation 2009 2009-12-29 /pmc/articles/PMC2801456/ /pubmed/20066161 http://dx.doi.org/10.1155/2009/348910 Text en Copyright © 2009 A. W. Oosten et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Oosten, A. W. Seynaeve, C. Schmitz, P. I. M. den Bakker, M. A. Verweij, J. Sleijfer, S. Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title | Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title_full | Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title_fullStr | Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title_full_unstemmed | Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title_short | Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin |
title_sort | outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801456/ https://www.ncbi.nlm.nih.gov/pubmed/20066161 http://dx.doi.org/10.1155/2009/348910 |
work_keys_str_mv | AT oostenaw outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin AT seynaevec outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin AT schmitzpim outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin AT denbakkerma outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin AT verweijj outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin AT sleijfers outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin |